誉衡药业(002437) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit of 100 million yuan for the first half of 2024, a significant increase compared to a net loss of 130 million yuan in the same period last year, representing a growth of 253.99% to 360.19%[3] - The net profit after deducting non-recurring gains and losses is projected to be 80 million yuan, compared to a loss of 100 million yuan in the previous year, indicating a growth of 198.80% to 273.50%[3] - Basic earnings per share are expected to be 0.0445 yuan, a recovery from a loss of 0.0579 yuan per share in the same period last year[3] Cost Management - The company has achieved noticeable results in cost reduction and efficiency improvement, with sales, management, and financial expenses all decreasing compared to the same period last year[11] Strategic Changes - The company sold its entire stake in Guangzhou Yuheng Biotechnology Co., which will no longer impact its financial results for the first half of 2024[5] - The company has continued to promote marketing reforms, resulting in rapid sales growth for core products such as An Nao Wan/Pian and injectable multivitamins[15] Government Support - In March 2024, a subsidiary received government subsidies amounting to 28.1269 million yuan, which positively impacted the net profit attributable to shareholders by 22.7125 million yuan, classified as non-recurring gains[16]